A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19.
EClinicalMedicine
; 48: 101450, 2022 Jun.
Article
in En
| MEDLINE
| ID: mdl-35582123
Full text:
1
Database:
MEDLINE
Type of study:
Clinical_trials
Language:
En
Journal:
EClinicalMedicine
Year:
2022
Type:
Article
Affiliation country:
Italy